RESEARCH ARTICLE

Check for updates

Repositioning Salirasib as a new antimalarial agent†

Exequiel O. J. Porta, [iD] ‡[a] Ignasi Bofill Verdaguer,‡[b] Consuelo Perez,[c] Claudia Banchio, [iD] [c] Mauro Ferreira de Azevedo,[d] Alejandro M. Katzin [iD] *[b] and Guillermo R. Labadie [iD] *[ae]

Malaria is a serious tropical disease that kills thousands of people every year, mainly in Africa, due to *Plasmodium falciparum* infections. Salirasib is a promising cancer drug candidate that interferes with the post-translational modification of Ras. This *S*-farnesyl thiosalicylate inhibits isoprenylcysteine carboxyl methyltransferase (ICMT), a validated target for cancer drug development. There is a high homology between the human and the parasite enzyme isoforms, in addition to being a druggable target. Looking to repurpose its structure as an antimalarial drug, a collection of *S*-substituted derivatives of thiosalicylic acid were prepared by introducing 1,2,3-triazole as a diversity entry point or by direct alkylation of the thiol. We further investigated the *in vitro* toxicity of FTS analogues to *Plasmodium falciparum* in the asexual stages and in Vero cells. An antiplasmodial activity assay was performed using a simple, high-sensitivity methodology based on nanoluciferase (NLuc)-transfected *P. falciparum* parasites. The results showed that some of the analogs were active at low micromolar concentration, including Salirasib. The most potent member of the series has *S*-farnesyl and the 1,2,3-triazole moiety substituted with phytyl. However, the compound substituted with methyl-naphthyl shows promising physicochemical and activity values. The low cytotoxicity in eukaryotic cells of the most active analogs provided good therapeutic indices, being starting-point candidates for future antimalarial drug development.

Malaria is one of the most serious tropical diseases, and the World Health Organization describes malaria as one of the top ten causes of death worldwide.[1] In 2016, malaria infected 216 million and killed more than 400 thousand people; most deaths occurred in Africa and were due to *Plasmodium falciparum* infections. To date, there are no vaccines for malaria immunization. Therefore, the disease prophylaxis, control and treatment are based on the existing chemotherapy and vector control.

[a] Instituto de Química Rosario, UNR, CONICET, Suipacha 531, S2002LRK, Rosario, Argentina. E-mail: labadie@iquir-conicet.gov.ar; Fax: +54 341 4370477; Tel: +54 341 4370477
[b] Departamento de Parasitología, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. E-mail: amkatzin@icb.usp.br
[c] Instituto de Biología Molecular y Celular (IBR-CONICET-UNR), Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, S2002LRK, Rosario, Argentina
[d] Departamento de Biociências, Universidade Federal de São Paulo, Santos, Brazil
[e] Departamento de Química Orgánica, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, S2002LRK, Rosario, Argentina
† Electronic supplementary information (ESI) available: Detailed experimental procedures. Copies of the ^{1}H and ^{13}C NMR spectra of all new products. See DOI: 10.1039/c9md00298g
‡ Both authors contributed equally to this work.

Currently, the WHO suggests the use of combination therapies for the treatment of malaria.[2] Unfortunately, its expanding resistance puts at risk the ongoing plans to control the disease.[3] For these reasons, new antimalarial compounds effective against *Plasmodium*'s asexual stages in humans are required to treat infected people and for use in collective eradication programs.[1,4]

To facilitate drug discovery, efforts are being made to develop more sensitive, robust, easier, and less expensive methods for drug screening.[5,6] Two well-known research strategies for the discovery of etiological treatments for parasitic protozoan diseases are drug repositioning and improving drug effectiveness through structural modifications.[7]

Salirasib (farnesyl thiosalicylic acid, FTS) is a promising drug candidate that was first reported more than 20 years ago.[8,9] This simple compound is a potent inhibitor of isoprenylcysteine carboxyl methyltransferase (ICMT) in cell-free systems. Surprisingly, its activity did not correlate with whole-cell experiments, being a poor methylation inhibitor. It has been shown that Salirasib acts on the Ras signaling cascade, which is required for cell proliferation and differentiation. This process starts with the removal of all Ras isoforms from their membrane anchoring sites.[10] Since its discovery, different clinical trials have been conducted using Salirasib for pancreatic, colon, lung and breast cancers.[11]

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, **10**, 1599–1605 | 1599

One possible target for the development of potential anti-malarial drugs is the isoprenoid biosynthesis.[12]

Isoprenoids are synthesized in *P. falciparum*, plant plas-tids and most bacteria (among other organisms) *via* the 2-*C*-methyl-D-erythritol-4-phosphate (MEP) pathway.[12] In contrast, most animal cells, several eubacteria, some archaea and fungi synthesize isoprenoid precursors only *via* the mevalonate pathway. In 2004, Goulart *et al.*[13] showed that for *P. falciparum* strain 3D7 cultured *in vitro*, FTS exhibits a dose–response growth inhibition effect with a half maximum inhibitory concentration (IC_{50}) of 14 μM (confidence interval: 13.61–19.18 μM). The greatest lethal effects were observed be-tween the schizont stage and the formation of rings.[13] The same authors showed that FTS specifically decreased radioac-tive uptake in immunoprecipitated Ras isoprenylated pro-teins radiolabeled with $[1\text{-}(n)\text{-}^3\text{H}]$ farnesyl pyrophosphate triammonium salt.[13] This effect was only observed in the schizont stage, for which the authors suggested a higher Ras protein expression.[13] It was also suggested that, as it occurs in other cell systems, Ras proteins could be involved in cell signaling or proliferation in the parasite.[14,15] Based on these precedents, we envisioned FTS as a promising scaffold to de-velop new antimalarial agents. To explore this hypothesis, a collection of thiosalicylic acid derivatives were prepared and assayed against *P. falciparum*.

Bioinformatics studies of the molecular target

In order to position ICMT as a possible molecular target for repositioning drugs, multiple sequence alignments and homology modelling were refined (Fig. S1†).[16] The primary human and infectious apicomplexan ICMT sequences (in particular, *Toxoplasma* and *Plasmodium* genera) were ana-lyzed. All the sequences correspond to functional proteins belonging to the ICMT superfamily containing a conserved C-terminal substrate-binding site, (particularly, between amino acids 160 and 279 in *H. sapiens*). There is com-plete conservation on the amino acids of the active site and those interacting with the *S*-adenosyl methionine co-factor. Particularly, there is a 36% identity and 54% simi-larity between *Hs*-ICMT and *Pf*-ICMT. These values are considerably higher when the domains involved in the cat-alytic sites are analyzed. Expanding the sequence analysis towards different species allows us to conclude that the catalytic domain of the enzyme is highly conserved throughout evolution (Fig. S2†). In addition, the TDR Tar-gets database[17] indicates that ICMT would be a druggable target and is potentially essential in *P. falciparum*. Promis-ingly, the TDR Targets database predicts that Salirasib would be a potential inhibitory drug for *Pf*-ICMT. Based on these facts, ICMT is an interesting molecular target and Salirasib is an attractive starting point for repositioning drugs toward *P. falciparum* and possible for use in consequent reengineering.

Design and synthesis

Salirasib activity has been undoubtedly linked to the pres-ence of thiosalicylic acid on the structure.[9] The simplicity of its structure only allowed minimal structural modifications to explore a structure–activity relationship and improve the activity. It has been observed that a free carboxyl group is ab-solutely required for its activity. Introduction of a halogenic substituent into the benzene ring causes a decrease or a loss of activity on the target.[18] Therefore, we decided to preserve the 2-mercaptobenzoic acid portion in our design and intro-duce modifications on the thiol group. The diversity was in-troduced by direct alkylation of the thiol, preparing a collec-tion of thioethers and additionally, further diversity was added by 1,2,3-triazol formation *via* click chemistry (Fig. 1).

First, to prepare the thioether collection, selective thiol al-kylation was optimized. Propargyl bromide was selected as an alkylating agent for that purpose because it was the key intermediate for the 1,2,3-triazole library preparation (Scheme 1).

Starting from commercial thiosalicylic acid, different reac-tions were assayed using different bases and solvents.

The attempts using potassium hydroxide and potassium car-bonate in water were unsuccessful (Table 1, entries 1 and 2).

When these bases were used, but the solvent was ex-changed with MeOH, KOH caused complete product decom-position and with K_2CO_3, an alkylated ester product was obtained (Table 1, entries 3 and 4). Fortunately, when using guanidinium carbonate as a base in acetone, a complete se-lectivity was achieved obtaining *S*-propargyl thiosalicylic acid **1** as the only product (Table 1, entry 5).

With those conditions optimized, we proceeded to prepare a collection of analogs. Alkylating agents were selected aiming to cover a wide spectrum of steric and lipophilic de-mands. Most of the required alkylating agents were commer-cial. For those not commercially accessible, bromides were easily prepared from the alcohol precursor by substitution with phosphorous tribromide in Et_2O. Isoprenols (geraniol, farnesol, and phytol) were transformed into their respective chlorides under the Corey–Kim modified conditions,[19] using *N*-chlorosuccinimide and DMS in DCM.

The final collection of the alkylated thiosalicylic acid was prepared by *S*-alkylation (Table 1, entry 5), using the opti-mized conditions providing twelve analogs with an average yield of 79% after purification by column chromatography (Scheme 2, Table 2, entries 1 to 11).


Fig. 1 Proposed Salirasib analogs.

1600 | *Med. Chem. Commun.*, 2019, **10**, 1599–1605

This journal is © The Royal Society of Chemistry 2019

Scheme 1 Alkylation of thiosalicylic acid.

Scheme 2 Preparation of alkylated thiosalicylic acid library.

Once the *S*-alkylated thiosalicylic acid collection was finished, we proceeded to synthesize the 1,2,3-triazole collection. A pool of azides were selected, following the same chemotype used for the alkylated products, and applied to prepare the new derivatives. Azides were mostly prepared by direct substitution of the bromide with sodium azide in DMF. For the isoprenyl azides, isoprenol was transformed in a one-pot reaction into azides, whose regioisomers are in equilibrium.[20] The triazoles were synthesized by the reaction of *S*-propargyl thiosalicylate **1** with the azide under conventional conditions using copper sulphate and sodium ascorbate in ^{t}BuOH : H$_2$O (1 : 1).[21] The collection of sixteen new products was obtained with an average yield of 81% after purification (Scheme 3, Table 2 entries 12 to 28).

Biological activity

In vitro activity against *P. falciparum*

The NanoLuc luciferase (NLuc) method for drug screening was applied and validated with results previously obtained[6] by the malaria SYBR Green I fluorescence assay (MSF). While the fluorescence-based method relied on quantifying fluorescence on parasite cultures previously incubated with the DNA intercalating dye, the most sensitive and affordable NLuc method involves quantification of bioluminescence in NLuc expressing transgenic parasites.[22] In order to confirm that the IC$_{50}$ values determined by both methods are similar and that the transgenic NLuc expressing parasites are not more resistant to known antimalarials, the wild type 3D7 strain and parasites transfected with the pEF-NLuc expressing vector[22] were cultured in serially diluted concentrations of artesunate for 48 h and the growth was quantified by the MSF and/or the NLuc assay. Non-linear regression of growth values generated by both methods produced similar IC$_{50}$ values suggesting that the results are comparable (Table S1†).

Once NLuc assay was validated, the prepared compounds were screened to select the most effective compounds. For this purpose, the parasites were cultured with FTS or its analogues at 200 μM concentration. The growth was quantified

daily by the NLuc assay and compared to that of parasites cultured with the solvent control ethanol. Because most compounds are soluble in ethanol, 200 μM is approximately the highest assayable drug concentration that does not produce significant effects due to ethanol toxicity (0.5–1% at maximum). The inhibition percentage caused by FTS and its analogues at the 200 μM concentration (as compared to an untreated control) was calculated three times. We also performed quality controls with antimalarial drugs, including 200 μM clindamycin (which is a delayed-effect antimalarial compound), both artesunate and chloroquine at 200 nM (as supralethal controls) and 3.125 nM artesunate (as a sublethal control). Compounds **2k** and **2m** showed haemolysis at 200 μM but not at 100 μM; for this reason, the inhibition percentage study was performed at 100 μM. The results showed that clindamycin, as well as FTS and most of its derivatives, had a higher inhibitory effect at 72 h than that after one or two days (Fig. S3†). On the other hand, inhibition by either sub- or supralethal artesunate concentrations was similar from 1–3 days. Considering the assays initiated with the ring stage parasites, the compounds likely act on late stage parasites as previously reported for FTS.

The IC$_{50}$ was determined for the FTS analogues which inhibited the parasite growth >90% after 72 h, an effect similar to the observed inhibition of antimalarial control drugs at supralethal concentrations (Table 2, Fig. S4†). The IC$_{50}$ values of chloroquine and artesunate were determined as positive and quality controls. The IC$_{50}$ was calculated at 72 h because this condition produced the best antimalarial effect and to be comparable with the previous FTS. We used an initial lethal maximum concentration of 200 μM for FTS (100 μM for compounds **2k** and **2m**) and its analogues, or 200 nM for chloroquine and artesunate, in addition to several smaller concentrations prepared by serial dilutions.

We also checked all the compounds for which the calculated IC$_{50}$ values indicated that they may have directly interfered with the NLuc luminescence emission (Fig. S3†). For this purpose, we added a 200 μM concentration of each prepared analog to 100 μL of parasite lysate prepared as

Table 1 Optimization of thiosalicylic *S*-alkylation

Entry	Reagents[a]	Results
1	KOH (1 eq.), H$_2$O	NR
2	K$_2$CO$_3$ (1 eq.), H$_2$O	NR
3	KOH (1 eq.), MeOH	Decomposition
4	K$_2$CO$_3$ (1 eq.), MeOH	*S*-Propargyl propargyl thiosalicylate
5	Guanidinium carbonate (1 eq.) acetone, r.t.	*S*-Propargyl thiosalicylic acid, 81% yield

[a] Thiosalicylic acid (1 eq.), propargyl bromide (1 eq.), reflux, 12 h.

Table 2 *In vitro* antimalarial activity and yield of alkylated thiosalicylic acid derivatives and of 1,2,3-triazolyl thiosalicylic acid derivatives

Entry	Cmpd	R	Yield (%)	*P. falciparum*[a] IC$_{50}$ μM	Z value	R^2
1	**1**	Propargyl	81	>200		
2	**1a**	Cyclohexyl	87	>200		
3	**1b**	Benzyl	73	>200		
4	**1c**	3-Phenyl-propyl	75	>200		
5	**1d**	Cinnamyl	68	>200		
6	**1e**	Octyl	83	>200		
7	**1f**	Decyl	81	>200		
8	**1g**	$CH_2CH_2CO_2CH_2CH_3$	78	>200		
9	**1h**	Prenyl	72	>200		
10	**1i**	Geranyl	88	>200		
11	**1j**	Farnesyl (Salirasib)	79	20.34 ± 5.52	0.93 ± 0.06	0.95 ± 0.02
12	**1k**	Phytyl	85	13.40 ± 1.53	0.93 ± 0.06	0.98 ± 0.02
13	**2a**	Cyclohexyl	84	>200		
14	**2b**	Benzyl	80	>200		
15	**2c**	3-Phenyl-propyl	88	>200		
16	**2d**	Cinnamyl	86	65.33 ± 10.71	0.89 ± 0.09	0.87 ± 0.01
17	**2e**	Octyl	78	>200		
18	**2f**	Decyl	88	>200		
19	**2g**	$CH_2CH_2CO_2CH_2CH_3$	91	>200		
20	**2h**	Prenyl	89	>200		
21	**2i**	Geranyl	84	>200		
22	**2j**	Farnesyl	90	25.97 ± 1.32	0.94 ± 0.06	0.96 ± 0.02
23	**2k**	Phytyl	83	9.75 ± 1.97	0.92 ± 0.06	0.98 ± 0.01
24	**2l**	$CH_2CO_2CH_2CH_3$	92	>200		
25	**2m**	Cetyl	81	14.44 ± 5.43	0.93 ± 0.06	0.97 ± 0.01
26	**2n**	Tridecanyl	55	19.83 ± 5.14	0.88 ± 0.08	0.97 ± 0.02
27	**2o**	2-Phenyl-ethyl	94	>200		
28	**2p**	2-Naphthylmethyl	33	20.54 ± 5.45	0.92 ± 0.06	0.96 ± 0.04
	CQ			8.15 ± 1.83 nM	0.75 ± 0.18	0.96 ± 0.02
	ART			1.64 ± 0.08 nM	0.86 ± 0.11	0.96 ± 0.03

CQ = chloroquine, ART = artesunate. [a] Evaluated by the NanoLuc luciferase method.

previously described from unsynchronized cultures (parasitaemia 1% and haematocrit 2%); we then counted the emitted luminescence with respect to a control without added experimental compounds. The results showed few luminescence modifications which is comparable to those results obtained by other author homologous assays for antimalarial drug screenings.[4,5] Again, in this assay, all the samples had Z > 0.5.

The *in vitro* antimalarial activity of the collection of *S*-alkylated thiosalicylic acid derivatives (compounds **1a–k**) is shown in Table 2 (entries 1–11). Most of the derivatives in this collection were inactive at the maximum concentration tested of 200 μM, including the key intermediate *S*-propargyl thiosalicylic acid **1**.

Interestingly, the only active compounds of the series were the prenylated analogs **1j** and **1k**. Compounds **1j** (R = *E*,*E*-farnesyl, Salirasib) and **1k** (R = phytyl) have IC$_{50}$ values of 20.34 and 13.40 μM, respectively. The derivatives with smaller prenyl

chains (**1h** R = prenyl and **1i** R = geranyl) were inactive at 200 μM, linking the activity with the number of isoprene units. This is not surprising having in mind that the early studies of thiosalicylic as prenylated protein methyl transferase inhibitors have shown it to be very sensitive to the nature of the prenyl chain, being inactive for the geranylated analogs.[18,23]

On the other hand, it is interesting to note that only the most voluminous molecules of this family that contain a fatty acid chain (**1j** and **1k**) are active in *P. falciparum*. Members with shorter chains are inactive (**1e** and **1f**). Finally, the remaining inactive analogs that have aromatic, carbocyclic or alkyl esters put some limits to the possible stereo-electronic variations on the structure.

The *in vitro* antimalarial activity of the collection of the 1,2,3-triazolyl thiosalicylic acid derivatives (compounds **2a–p**) is presented in Table 2 (entries 13–28). The behavior of this collection is similar to that of the *S*-alkylated analogs with long fatty substituents providing a better activity. A detailed look on the activities shows that compounds **2a**, **2b**, **2c**, **2e**, **2f**, **2g**, **2h**, **2i**, **2l** and **2o** did not display activity on *P. falciparum* at the maximum concentration tested (200 μM).

The remaining six analogs displayed IC$_{50}$ values in the range of 65.33 μM, for the cinnamyl derivative **2d**, to 9.75 μM for the phytyl analog **2k**, the most active compounds of both collections (twice as active as Salirasib). A detailed look on the nature of the substituents that provide better activities

Scheme 3 1,2,3-Triazolyl thiosalicylate derivatives.

1602 | *Med. Chem. Commun.*, 2019, **10**, 1599–1605

This journal is © The Royal Society of Chemistry 2019

revealed again that farnesyl (**2j**), phytyl (**2k**), and long alkyl linear chains (**2m** = cetyl and **2n** = tridecanyl) are among the most active. But in this case, the aromatic substituted derivatives **2d** (cinnamyl) and **2p** (methyl naphthyl) also appeared among the most active, while compounds **2b** (benzyl), **2c** (3-phenyl propyl) and **2o** (2-phenyl ethyl) are not active at concentrations below 200 μM.

In vitro cytotoxicity assay in Vero cells

The collection prepared was assayed against Vero cells (ATCC CCL-81, already available in our laboratory) to determine the selectivity against *P. falciparum*. The initial screening showed that all the compounds were non-cytotoxic at the maximum concentration tested of 4.75 μg mL^{-1}. Then, a selection of the most active analogs was subjected to a full analysis to determine the IC$_{50}$.

Compounds **1j**, **1k**, **2d**, **2j**, **2k**, **2m**, **2n** and **2p** were assayed showing different degrees of cytotoxicity as was expected because they have an anticancer origin (Table 3). The most toxic compound, analog **2l**, has an IC$_{50}$ of 34 μM while the less toxic analogs, compounds **1j**, **2d** and **2j**, were inactive at the maximum concentration tested of 200 μM. A detailed analysis on the activities shows that compounds with long aliphatic or prenyl chains are the most cytotoxic derivatives. That is the case for analogs **1k**, **2k**, **2m**, **2n** and **2p** that have IC$_{50}$ values below 60 μM, but there is no case where their selectivity index is lower than 1.8. Taking these values into consideration, the best selected analogs of the series were compounds **1j**, **2j** and **2p** that have therapeutic indices of 10.3, >7.70 and 6.95, respectively. According to these values, the analogues can be considered as promising starting point candidates[24] to move to further *in vivo* studies.

ADME-Tox calculations

An oral drug requires good bioavailability that can be achieved by balancing its partitioning and solubility properties. These properties are difficult to achieve on any drug development pipeline. Indeed, one third of new chemical entities have poor pharmacokinetic properties and have not been able to reach the clinical trial phase. To avoid these problems, an early estimation of ADME-Tox properties seems mandatory in any drug discovery program. The *in silico*

ADME-Tox gave substantial information for the feasible and pharmacotherapeutic use of the chemical library.

To rationalize the profile of our analogs, computational studies of all the synthesized compounds were performed to predict their absorption, distribution, metabolism and excretion (ADME) properties, Lipinski's rule of five, toxicity liabilities and drug likeness. The calculations were performed using web-based software Molinspiration,[25] Osiris,[26] ChemAxon,[27] and SwissADME.[28] The Molinspiration platform uses a sum of fragment-based contributions and correction factors being able to calculate the parameters of most of the organic and even organometallic molecules. The analysis of the collection revealed that only two compounds have a MW >500. Almost half of them (13 analogs) violated the rule with log *P* > 5. However, our library contains ionizable groups that are charged at physiological pH, which make log *D* a better descriptor of the lipophilicity of these molecules. The calculated log *D* at physiological pH (7.4) of the collection shows that 93% of the library have values ≤5 (−1.62 to 6.31). Finally, all the compounds fulfill the restrictions on the number of hydrogen donors and acceptors. The physicochemical profile and distribution of the prepared compounds based on their molecular weight, polar surface area, log *D* and octanol/water partition coefficient are shown in Fig. 2.

The OSIRIS Property Explorer platform was used to perform a toxicology analysis while also providing the drug likeness and a drug score. The results revealed that none of the products prepared are potentially mutagenic, irritant,

Table 3 Cytotoxicity of the selected analogs

Entry	Cmpd	Family/R	Vero cells IC$_{50}$ μM	SI
1	**1j**	*S*-Alk/farnesyl	210 ± 5	10.3
2	**1k**	*S*-Alk/phytyl	52 ± 4	3.87
3	**2d**	123T/cinnamyl	>200	>3.06
4	**2j**	123T/farnesyl	>200	>7.70
5	**2k**	123T/phytyl	34 ± 1	3.67
6	**2m**	123T/cetyl	27 ± 4	1.86
7	**2n**	123T/tridecanyl	59 ± 4	2.99
8	**2p**	123T/naphthyl	143 ± 6	6.95

SI = selectivity index. Calculated as IC$_{50}$ (Vero cells)/IC$_{50}$ (*P. falciparum*).

Fig. 2 Distribution of physicochemical parameters of the chemical library.

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, **10**, 1599–1605 | **1603**

teratogenic or toxic for sexual reproduction. The solubility is a critical property which aids in the circulation of a drug after the administration and into the bloodstream. The calculated drug likeness shows a variable profile with thirteen derivatives having a poor profile (<-3), but the remaining derivatives fall between -3 and 0. The combination of solubility, $\log P$, MW and toxicity risk is used to calculate the drug scores, which were from moderate to good compared with that of a standard drug (0.13–0.61).

Even though there are diverse routes of drug administration, oral dosing is highly preferred, especially for tropical diseases. Early estimation of oral bioavailability (for example, the fraction of the dose that reaches the bloodstream after oral administration) is very useful in the drug development pipeline. Bioavailability is highly multifactorial but is primarily driven by gastrointestinal absorption. SwissADME use the BOILED-Egg method to predict the gastrointestinal absorption and brain penetration of small molecules. At this point, among all the active compounds, the one that stands out the most is compound **2p**.

A good proportion of the analogs did not meet the $\log P$ requirement. However, the analogs contain ionizable groups, so the $\log D$ values calculated at physiological pH are more adequate. We wanted to find a correlation between the compound activity and its partition coefficient. A chart correlating the *P. falciparum* IC_{50} *vs.* $\log D$ presented in Fig. 3 (on top) showed a clear pattern. An interesting outcome of this chart is the location of the most active compounds. On the one hand, a region of "high activity" can be defined with all

the compounds having $\log D > 3$. On the other hand, the remaining analogs were inactive except for the methyl-naphthyl derivative **2p**. The tendency shows that the highest activity for the library is concentrated for the analogs with $\log D$ between 4.7 and 6.5, with a maximum value of 6 (Fig. 3, bottom). The analog **2p** seems to conjugate good activity, excellent ADME-Tox values and appropriate physico-chemical parameters. Likewise, the difference in the physico-chemical properties with respect to the other active molecules of the family suggests that the compound **2p** would exert a different mechanism of action.

Conclusions

Drug repositioning has emerged as a valuable strategy for the development of new treatments against tropical diseases including malaria. Drug repurposing and reengineering have been shown as efficient strategies to reduce the cost and time of drug development. Almost 40% of drugs registered by the US FDA found new uses in the treatment of several human diseases.[29] Based on that premise, we selected Salirasib as a starting point to reengineer the anticancer drug as a new antimalarial agent, preparing a library of new 28 thiosalicylic acid derivatives. The whole collection was tested against *P. falciparum*, the etiological agent of malaria. The selectivity towards *P. falciparum* in comparison with Vero cells could point Salirasib as an example of drug repositioning. Moreover, an island of high activity was found for the derivatives substituted with long alkyl chains or the farnesyl terpene derivative. Compound **2k** is the most active structure against *P. falciparum* (IC_{50} of 9.75 μM, SI of 3.67). Some compounds have high $\log P$ values breaking Lipinski's rules, but $\log D$ calculated at physiological pH seems to be a better descriptor, based on the ionizable groups on the prepared analogs. The naphthyl derivative **2p** has an antimalarial activity profile similar to Salirasib, good ADME-Tox parameters and an excellent drug score being the best candidate as an antiplasmodial agent. The lack of toxicity of **2p** (predicted *in silico* and validated on Vero cells) together with its structural simplicity prompted us to point out this new analog as a starting point candidate for future antimalarial drug development. The most active members of the collection have activity values that are comparable to other examples of drug repositioning towards malaria, such as verteporfin, amlodipine besylate, triamterene, rocuronium bromide, or apoptozole.[30,31] The same conclusion can be reached if the examples of repositioning towards other parasitic diseases are analyzed.[32,33] However, in some cases, the selectivity index is low, or they break more than one of Lipinski's rules. Finally, further optimization would be required for the series to become a serious candidate for future drug development.


Fig. 3 Top: Correlation between the *in vitro* antimalarial activity and $\log D$. Bottom: Expansion of the "high activity" area and tendency.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

References

1 WHO, World malaria report 2017.

2 J. N. Burrows, S. Duparc, W. E. Gutteridge, R. Hooft van Huijsduijnen, W. Kaszubska, F. Macintyre, S. Mazzuri, J. J. Möhrle and T. N. C. Wells, *Malar. J.*, 2017, **16**, 26.

3 A. M. Dondorp, F. M. Smithuis, C. Woodrow and L. von Seidlein, *Trends Parasitol.*, 2017, **33**, 353–363.

4 J. T. Griffin, T. D. Hollingsworth, L. C. Okell, T. S. Churcher, M. White, W. Hinsley, T. Bousema, C. J. Drakeley, N. M. Ferguson, M. G. Basáñez and A. C. Ghani, *PLoS Med.*, 2010, **7**, e1000324.

5 D. A. Fidock, P. J. Rosenthal, S. L. Croft, R. Brun and S. Nwaka, *Nat. Rev. Drug Discovery*, 2004, **3**, 509–520.

6 M. Smilkstein, N. Sriwilaijaroen, J. X. Kelly, P. Wilairat and M. Riscoe, *Antimicrob. Agents Chemother.*, 2004, **48**, 1803–1806.

7 K. T. Andrews, G. Fisher and T. S. Skinner-Adams, *Int. J. Parasitol.: Drugs Drug Resist.*, 2014, **4**, 95–111.

8 M. Marom, R. Haklai, G. Ben-Baruch, D. Marciano, Y. Egozi and Y. Kloog, *Cancer Res.*, 1995, **270**, 22263–22270.

9 D. Marciano, G. Ben-Baruch, M. Marom, Y. Egozi, R. Haklai and Y. Kloog, *J. Med. Chem.*, 1995, **38**, 1267–1272.

10 E. Bustinza-Linares, R. Kurzrock and A. M. Tsimberidou, *Future Oncol.*, 2010, **6**, 885–891.

11 A. M. Tsimberidou, M. A. Rudek, D. Hong, C. S. Ng, J. Blair, H. Goldsweig and R. Kurzrock, *Cancer Chemother. Pharmacol.*, 2010, **65**, 235–241.

12 F. M. Jordão, E. A. Kimura and A. M. Katzin, *Mem. Inst. Oswaldo Cruz*, 2011, **106**, 134–141.

13 H. R. Goulart, E. A. Kimura, V. J. Peres, A. S. Couto, F. A. A. Duarte and A. M. Katzin, *Antimicrob. Agents Chemother.*, 2004, **48**, 2502–2509.

14 J. Thélu, V. Bracchi, J. Burnod and P. Ambroise-Thomas, *Cell. Signalling*, 1994, **6**, 777–782.

15 J. E. Gisselberg, L. Zhang, J. E. Elias and E. Yeh, *Mol. Cell. Proteomics*, 2017, **16**, S54–S64.

16 C. Notredame, D. G. Higgins and J. Heringa, *J. Mol. Biol.*, 2000, **302**, 205–217.

17 F. Agüero, B. Al-Lazikani, M. Aslett, M. Berriman, F. S. Buckner, R. K. Campbell, S. Carmona, I. M. Carruthers, A. W. Chan, F. Chen, G. J. Crowther, M. A. Doyle, C. Hertz-Fowler, A. L. Hopkins, G. McAllister, S. Nwaka, J. P. Overington, A. Pain, G. V. Paolini, U. Pieper, S. A. Ralph, A. Riechers, D. S. Roos, A. Sali, D. Shanmugam, T. Suzuki, W. C. Van Voorhis and C. L. Verlinde, *Nat. Rev. Drug Discovery*, 2008, **7**, 900–907.

18 D. Marciano, Z. Aharonson, T. Varsano, R. Haklai and Y. Kloog, *Bioorg. Med. Chem. Lett.*, 1997, **7**, 1709–1714.

19 G. R. Labadie, R. Viswanathan and C. D. Poulter, *J. Org. Chem.*, 2007, **72**, 9291–9297.

20 E. O. J. Porta, M. M. Vallejos, A. B. J. Bracca and G. R. Labadie, *RSC Adv.*, 2017, **7**, 47527–47538.

21 E. O. J. Porta, S. N. Jäger, I. Nocito, G. I. Lepesheva, E. C. Serra, B. L. Tekwani and G. R. Labadie, *MedChemComm*, 2017, **8**, 1015–1021.

22 M. F. Azevedo, C. Q. Nie, B. Elsworth, S. C. Charnaud, P. R. Sanders, B. S. Crabb and P. R. Gilson, *PLoS One*, 2014, **9**, e112571.

23 Z. Aharonson, M. Gana-Weisz, T. Varsano, R. Haklai, D. Marciano and Y. Kloog, *Biochim. Biophys. Acta, Mol. Basis Dis.*, 1998, **1406**, 40–50.

24 P. Y. Muller and M. N. Milton, *Nat. Rev. Drug Discovery*, 2012, **11**, 751–761.

25 *Molinspiration v2014.11*, 2014, http://www.molinspiration.com (accessed May 11, 2018).

26 *Osiris version 2*, https://www.organic-chemistry.org/prog/peo/ (accessed May 11, 2018).

27 *ChemAxon Calculator and Predictors*, https://chemaxon.com/products/calculators-and-predictors (accessed October 24, 2018).

28 A. Daina, O. Michielin and V. Zoete, *Sci. Rep.*, 2017, **7**, 42717.

29 T. T. Ashburn and K. B. Thor, *Nat. Rev. Drug Discovery*, 2004, **3**, 673–683.

30 N. Madassary Pazhayam, J. Chhibber-Goel and A. Sharma, *Drug Discovery Today*, 2019, **24**, 263–271.

31 Y. Chen, C. Murillo-Solano, M. G. Kirkpatrick, T. Antoshchenko, H. W. Park and J. C. Pizarro, *Sci. Rep.*, 2018, **8**, 10333.

32 M. R. Simões-Silva, J. S. De Araújo, G. M. Oliveira, K. C. Demarque, R. B. Peres, I. D'Almeida-Melo, D. G. J. Batista, C. F. Da Silva, C. Cardoso-Santos, P. B. Da Silva, M. M. Batista, M. T. Bahia and M. N. C. Soeiro, *Biochem. Pharmacol.*, 2017, **145**, 46–53.

33 M. Dichiara, A. Marrazzo, O. Prezzavento, S. Collina, A. Rescifina and E. Amata, *ChemMedChem*, 2017, **12**, 1235–1253.

This journal is © The Royal Society of Chemistry 2019

Med. Chem. Commun., 2019, **10**, 1599–1605 | **1605**